China CRO Industry Leaders Share R&D Risks

Local policies are leading to market segmentation and price wars, which compress profits and negatively affect research and development investment. Gross profit margins are segmented: zero-cost CROs have 30-40%, integrated CXOs 35-45%, and small molecule CDMOs approximately 30%. Geopolitical policies are causing market segmentation, price wars, profit compression, reduced R&D investment, and decreased technical competitiveness, leading to client loss. Price wars are compressing profits, impacting R&D investment, and reducing technological competitiveness, leading to customer loss. Small and medium-sized enterprises struggle to secure long-term orders from large pharmaceutical companies due to limited capabilities. Different business types show distinct gross profit margins: zero-cost CRO (30-40%), comprehensive CXO (35-45%), and small molecule CDMO (~30%). Related funds have seen declines in recent years, impacting investor returns. The Chinese CRO industry faces increased compliance costs and management difficulty due to international regulations, alongside geopolitical risks causing market segmentation. The Contract Research Organization (CRO) industry in China is experiencing adjustments in industry policies, leading to declines in related funds in previous years and poor investor returns. Smaller CROs, however, face limitations in securing long-term orders from large pharmaceutical companies, and different sub-sectors show revenue fluctuations due to varying cycles. While the industry is high-tech, the source questions if 'millions of high-speed growth' accurately reflects the industry's overall characteristic, particularly regarding profitability, and advises investors to diversify regional risks through globally-structured companies.